Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akorn Inc.

www.akorn.com

Latest From Akorn Inc.

Akorn Defaults On Loan Agreement After Sale Bid Falls Flat

Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.

Strategy Legal Issues

Deal Watch: Vir Partnering With Alnylam, WuXi On Coronavirus Treatments

US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.

Deals M & A

Akorn Extends Lenders Standstill With Aim To Sell Company

US generics company Akorn, which has been struggling since Germany’s Fresenius walked away from a $4.3bn merger three years ago, plans to put itself up for sale under an extended standstill agreement with lenders.

Strategy United States

US FDA Seeks Withdrawal Of Injectable Bacitracin Despite Extensive Off-Label Use

Injectable bacitracin, often used as a surgical irrigant, carries serious risks of nephrotoxicity and anaphylaxis; product is no longer prescribed for its lone approved indication in pediatric pneumonia. FDA’s decision aligns with advisory committee recommendations in 1984 and 2019.

Drug Safety Generic Drugs
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
    • Radiopharmaceuticals, Contrast Agents
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Akorn Inc.
  • Senior Management
  • Raj Rai, CEO
    Duane A Portwood, CFO
    Jonathan Kafer, EVP, Sales & Mktg.
    Bruce Kutinsky, PharmD, COO
    Steve Lichter, EVP, Pharma Ops
    Randall E Pollard, Chief Accounting Officer
  • Contact Info
  • Akorn Inc.
    Phone: (800) 932-5676
    1925 West Field Ct.
    Ste. 300
    Lake Forest, IL 60045
    USA
UsernamePublicRestriction

Register